Findings by an International Collaboration on SJS/TEN With Severe Ocular Complications

Mayumi Ueta*
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan

Stevens-Johnson Syndrome (SJS) is an acute inflammatory vesiculobullous reaction of the skin and mucosa, e.g., the ocular surface, oral cavity, and genitals. In patients with extensive skin detachment and a poor prognosis, the condition is called toxic epidermal necrolysis (TEN). Not all, but some patients with SJS/TEN manifest severe ocular lesions. Approximately 50% of SJS/TEN patients diagnosed by dermatologists and in burn units suffer from severe ocular complications (SOC) such as severe conjunctivitis with pseudomembrane and ocular surface epithelial defects in the acute stage. In the chronic stage, this results in sequelae such as severe dry eye and visual disturbance. Before 2005, our group of Japanese scientists started focusing on ophthalmic SJS/TEN with SOC. We found that cold medicines were the main causative drugs of SJS/TEN with SOC and that in Japanese patients, HLA-A*02:06 and HLA-B*44:03 were significantly associated with cold medicine-related SJS/TEN with SOC (CM-SJS/TEN with SOC). We expanded our studies and joined scientists from Korea, Brazil, India, Taiwan, Thailand, and the United Kingdom in an international collaboration to detect the genetic predisposition for SJS/TEN with SOC. This collaboration suggested that in Japanese patients, cold medicines, including NSAIDs, were the main causative drugs, and that HLA-A*02:06 was implicated in Japanese and Korean patients and HLA-B*44:03 in Japanese-, Indian-, and European ancestry Brazilian patients. Our joint findings reveal that there are ethnic differences in the HLA types associated with SJS/TEN with SOC.

Keywords: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), severe ocular complications (SOC), HLA, cold medicine

INTRODUCTION

Stevens-Johnson syndrome (SJS) is an acute inflammatory vesiculobullous reaction of the mucosa of the ocular surface, oral cavity, and genitals, and of the skin. In patients with extensive skin detachment and a poor prognosis, the condition is called toxic epidermal necrolysis (TEN). In the acute stage of SJS/TEN, approximately 50% of patients present with severe ocular lesions such as severe conjunctivitis with pseudomembrane and ocular surface epithelial defects (1).

Ophthalmologists encounter patients not only in the acute- but also the chronic stage. Dermatologists, on the other hand, tend to see SJS/TEN patients only in the acute stage, although in some countries such as France and Germany dermatologists also followed up the patients long time. Our ophthalmologic diagnosis of SJS/TEN was based on a confirmed history of acute-onset high fever, serious mucocutaneous illness with skin eruptions, and involvement of at least two mucosal sites, including the ocular surface (2–9). SJS/TEN patients with severe ocular complications (SOC)
in the acute stage often develop sequelae such as vision loss and very severe dry eye that prevent their having a normal life (10).

We defined acute-stage SOC as a condition with severe conjunctivitis with pseudomembrane and epithelial defects on the ocular surface (cornea and/or conjunctiva) (11). Chronic-stage SOC was defined as a condition with sequelae such as severe dry eye, trichiasis, symblepharon, and conjunctival invasion into the cornea (Figure 1A) (10). Ophthalmologists tend to diagnose both SJS and TEN with SOC broadly as “ophthalmic SJS” (Figure 1B) (4).

Dermatologists and others reported anticonvulsants such as carbamazepine and allopurinol (a uric acid-lowering drug) as being the main SJS/TEN-inciting drugs (12), while Japanese dermatologists reported that NSAIDs and multi-ingredient cold medications were main causative drugs for SJS/TEN (13). HLA analyses have shown that a genetic predisposition plays a role in the response to disease-eliciting drugs. Carbamazepine-induced SJS/TEN manifested a very strong association with the HLA-\(B^*15:02\) allele in Taiwanese Han Chinese patients (14), and the HLA-\(A^*31:01\) allele was strongly associated with carbamazepine-induced SJS/TEN in Japanese- (15) and European patients (16), the HLA-\(B^*57:01\) allele was associated with carbamazepine-induced SJS/TEN in European patients (17). Allopurinol-induced SJS/TEN was strongly associated with HLA-\(B^* 58:01\) in Han Chinese- (18), European ancestry- (19), and Japanese patients (20). Interestingly, not all patients with carbamazepine-induced SJS/TEN develop SOC (21). Allopurinol has been reported to elicit SJS/TEN without SOC (22).

We reported that about 80% of SJS/TEN with SOC patients seen at the Kyoto Prefectural University of Medicine developed SJS/TEN within several days after taking cold medicines (we recognized the onset of SJS/TEN when the patients had eruptions) (8).

These included multi-ingredient cold medications and non-steroidal anti-inflammatory drugs (NSAIDs) (2, 4, 6, 8, 23). Our Brazilian collaborators found that 53% of their SJS/TEN with SOC patients had taken cold medicines (24) as had 69% of Thai patients with SJS/TEN with SOC (25), and 50% of Taiwanese patients (26). Our Korean collaborators suspected that NSAIDs and cold medicines were associated with SOC in their SJS/TEN patients (27). These observations suggest that such medicines are major causative drugs in SJS/TEN with SOC patients of different ethnicities.

This mini-review cites the results of our international collaborative efforts to identify the genetic predisposition for SJS/TEN with SOC.

**HLA TYPES ASSOCIATED WITH SJS/TEN WITH SOC**

The extreme rarity of cutaneous and ocular surface reactions to drugs led us to suspect individual susceptibility. Therefore, we entered an international collaboration to analyze the association between HLA genotypes and SJS/TEN with SOC.

**Japan**

In 2007, our Japanese group first reported the HLA types associated with SJS/TEN with SOC; the ocular disease was strongly associated with HLA-\(A^*02:06\) [40 patients, 113 controls; odds ratio (OR) = 5.1, \(p = 0.00003\)] (28). Finding that about 80% of our Japanese SJS/TEN with SOC patients developed SJS/TEN after taking cold medicines to combat the common cold (8), we started to focus on cold medicine-related SJS/TEN (CM-SJS/TEN) with SOC. We reported that the ocular disease was strongly associated with HLA-\(A^*02:06\) [151 patients, 639 controls; (OR = 5.6, \(p = 2.7 \times 10^{-20}\)] and significantly associated with HLA-\(B^*44:03\) [151 patients, 639 controls; OR = 2.0, \(p = 1.3 \times 10^{-3}\)] (2). These HLA genotypes were not associated with cold medicine-unrelated, i.e., other medicine-related SJS/TEN with SOC (2). This suggested that the associated HLA genotypes were different and depended on the causative drug(s) (2, 4, 29). Moreover, HLA-\(A^*02:06\) and HLA-\(B^*44:03\) were not associated with CM-SJS/TEN without SOC (2), suggesting that different HLA genotypes were involved in the development of SJS/TEN with- and without SOC (2).

We reported that the main causative drugs for SJS/TEN with SOC in Japanese patients were cold medicines, including multi-ingredient cold medications and NSAIDs taken to combat the common cold. As we also found that acetaminophen, present in various cold medicines, was the most frequently implicated...
causative drug (2, 30), we focused on acetaminophen-related SJS/TEN with SOC. Analysis of the involved HLA types revealed that HLA-A*02:06 was strongly associated with acetaminophen-related SJS/TEN with SOC [80 patients, 113 controls; OR = 5.4, $p = 8.0 \times 10^{-7}$] (30).

**Korea**

Together with our Korean collaborators we investigated the HLA types (HLA-A*02:06 and HLA-B*44:03) that were associated with CM-SJS/TEN with SOC in Japanese patients. We compared ours with samples from Korean patients and found that in Koreans, CM-SJS/TEN with SOC was also significantly associated with HLA-A*02:06 (31 patients, 90 controls; OR = 3.0, $p = 0.018$), but not with HLA-B*44:03 (3).

Our Korean collaborators suspected that NSAIDs and cold medicines were associated with SOC in Korean patients with SJS/TEN (27). They reported that allopurinol-induced SJS/TEN might not elicit serious acute or chronic complications of the ocular surface (22).

They then focused on Korean CM-SJS/TEN with SOC and investigated all of HLA-class I (HLA-A, HLA-B, HLA-C). In their patients they identified HLA-A*02:06 (40 patients, 120 controls; OR = 3.0, $p = 0.0083$) and HLA-C*03:04 (40 patients, 120 controls; OR = 3.5, $p = 0.010$) as potential positive markers for CM-SJS/TEN with SOC, and HLA-C*03:03 (40 patients, 120 controls; OR = 0.10, $p = 0.0056$) as a possible indicator of protection against CM-SJS/TEN with SOC in the Korean population (31).

**Brazil**

Together with our Brazilian collaborators we investigated the HLA types (HLA-A*02:06 and HLA-B*44:03) that were associated with Japanese CM-SJS/TEN with SOC. Comparison of our and Brazilian samples revealed that in Brazilian CM-SJS/TEN with SOC, there was a significant association with HLA-B*44:03 (39 patients, 134 controls; OR = 2.7, $p = 0.024$), but not with HLA-A*02:06, a genotype not found in all Brazilian population (3). Interestingly, focused on European ancestry of Brazilians, the association with HLA-B*44:03 was stronger (15 patients, 62 controls; OR = 6.2, $p = 0.0037$) than in all Brazilians (3).

As the Brazilian collaborators found that 53% of their SJS/TEN with SOC patients had taken cold medicines before disease onset (24), they investigated the associated HLA types of CM-SJS/TEN with SJS/TEN with SOCs. Their studies suggested HLA-A*66:01 as a potential marker for CM-SJS/TEN with SOCs in Brazilians (39 patients, 133 controls; OR = 24.0, $p < 0.001$) of both Pardo- (19 patients, 66 controls; OR = 12.2, $p = 0.03$) and European ancestry (16 patients, 61 controls; OR = 21.2, $p = 0.04$) and that HLA-B*44:03 (16 patients, 61 controls; OR = 5.50, $p = 0.01$) and HLA-C*12:03 (16 patients, 61 controls; OR = 8.79, $p = 0.008$) might be markers only in individuals of European ancestry. Moreover, they stated that HLA-A*11:01 (39 patients, 133 controls; OR = 0.074, $p = 0.008$) might be a marker of resistance to CM-SJS/TEN with SOC (24).

Because Dipyrone was broadly used as cold medicine in Brazil, we also focused on dipyrone-related SJS/TEN with SOCs and found that HLA-B*44:03 (carrier frequency: $p = 0.002$, $p_{C} = 0.02$, OR = 8.8; gene frequency: $p = 0.001$, $p_{C} = 0.01$, OR = 7.5) and HLA-DQB1*04:02 (gene frequency: $p = 0.003$, $p_{C} = 0.03$, OR = 12.6) were significantly associated with cases of dipyrone-related SJS/TEN with SOCs in the Brazilian population of European ancestry, and that HLA-C*05:01 (carrier frequency: $p = 0.001$, $p_{C} = 0.01$, OR = 9.4; gene frequency: $p = 0.002$, $p_{C} = 0.02$, OR = 15.0) was significantly associated with cases of dipyrone-related SJS/TEN with SOCs in the Brazilian population of mixed race ancestry (32).

**India**

Together with our Indian collaborators we investigated the HLA types (HLA-A*02:06 and HLA-B*44:03) associated with Japanese CM-SJS/TEN with SOC.

In samples from Indian patients with CM-SJS/TEN with SOC there was a significant association with HLA-B*44:03 (20 patients, 55 controls; OR = 12.3, $p = 1.1 \times 10^{-5}$), but not with HLA-A*02:06 (3). Although the number of Indian patients was small, the association between Indian CM-SJS/TEN with SOC and HLA-B*44:03 was strong and significant (3).

According to Kannabiran et al. (33), Indian ophthalmologists found it difficult to obtain a detailed history of disease onset from their SJS/TEN with SOC patients and in many patients they could not identify causative drugs. HLA analysis showed that HLA-A*33:03 (80 patients, 50 controls; OR = 3.4, $p = 2.7 \times 10^{-3}$), HLA-B*44:03 (80 patients, 50 controls; OR = 12.2, $p = 7.3 \times 10^{-9}$), and HLA-C*07:01 (80 patients, 50 controls; OR = 6.5, $p = 4.4 \times 10^{-6}$) were risk alleles. HLA-B*57:01 (80 patients, 50 controls; OR = 0.05, $p = 3.0 \times 10^{-4}$) and HLA-C*06:02 (80 patients, 50 controls; OR = 0.1, $p = 4.0 \times 10^{-4}$) were protective alleles in the Indian population. Haplotypes comprised of HLA-B*44:03 and HLA-C*07:01 were strongly associated with SJS/TEN with SOC in the Indian population (80 patients, 50 controls; OR = 11.0, $p = 1.1 \times 10^{-7}$) (33).

**Thailand**

Together with our Thai collaborators we investigated causative drugs in their SJS/TEN with SOC patients and performed HLA analysis using Thai samples. HLA-A*33:03 (71 patients, 159 controls; OR = 2.6 $p = 0.0028$), HLA-B*44:03 (71 patients, 159 controls; OR = 6.0, $p < 0.0001$), and HLA-C*07:01 (71 patients, 159 controls; OR = 4.9, $p < 0.0001$) exhibited a significant associations with SJS/TEN with SOC (25). Among 71 Thai SJS/TEN with SOC patients, 49 (69%) had a history of taking cold medications prior to SJS/TEN onset.

A focus on CM-SJS/TEN with SOC revealed that HLA-B*44:03 (49 patients, 159 controls; OR = 7.2, $p < 0.0001$) and HLA-C*07:01 (49 patients, 159 controls; OR = 6.1, $p < 0.0001$) were significantly associated with Thai CM-SJS/TEN with SOC. In 17 of 49 patients with CM-SJS/TEN with SOC (34.7%), a haplotype comprised of HLA-B*44:03 and HLA-C*07:01 was present. This was the case in only 11 of 159 controls (6.9 %) (OR = 7.1, $p = 5.5 \times 10^{-6}$), suggesting that the HLA-B*44:03—HLA-C*07:01 haplotype was a potential risk factor for CM-SJS/TEN with SOC in the Thai population (25).

In Thailand, as in the USA and UK, cold medicines, especially acetaminophen (paracetamol), are widely-used over-the-counter...
drugs. Elsewhere we reported that in Japan, acetaminophen is the most frequently included drug in various cold medicines (2, 30). Therefore, we focused on Japanese acetaminophen-related SJS/TEN with SOC and analyzed the HLA types (30). Together with our Thai collaborators we also investigated Thai patients with acetaminophen-related SJS/TEN with SOC and analyzed the HLA types. Jongkhajornpong et al. (34) reported a significant association with HLA-A*33:03 (20 patients, 60 controls; OR = 5.4, \( p = 0.0030 \)), HLA-B*44:03 (20 patients, 60 controls; OR = 9.0, \( p = 0.0004 \)), HLA-C*07:01 (20 patients, 60 controls; \( p = 0.0002 \)), and the HLA-B*44:03—HLA-C*07:01 haplotype (20 patients, 60 controls; \( p = 9.0, p < 0.001 \)) in Thai patients with acetaminophen-related SJS/TEN with SOC, suggesting that they may have a role in the pathogenesis of SOC in acetaminophen-related SJS/TEN.

**Taiwan**

Our Taiwanese collaborators found that the main causative drugs in 26 Han Chinese with SJS/TEN with SOC were cold medicines; in 13 of 26 patients with SOC, cold medicines were the causative drugs, in none of 7 patients without SOC they identified cold medications as causative (26). Their findings echoed earlier studies that implicated cold medicines in the development of SOC in 80% of Japanese SJS/TEN patients (2, 35), 53% of Brazilian patients (24), and 69% of Thai patients (25).

Together with our Taiwanese collaborators we performed HLA analysis of SJS/TEN with SOC in the Han Chinese and found that HLA-A*02:07 (26 patients, 98 controls; OR = 3.2, \( p = 0.049 \)) was associated with their development of the disease. Our focus on CM-SJS/TEN with SOC revealed that HLA-A*02:07 (13 patients, 98 controls; OR = 5.6, \( p = 0.016 \)) was strongly associated with the development of SOC among Han Chinese CM-SJS/TEN patients (26). Single amino acid substitutions in major histocompatibility complex (MHC) class I molecules were found to play a role in distinct peptide repertoires. For example, three HLA-A2 subtypes, i.e., HLA-A*02:04, HLA-A*02:06, and HLA-A*02:07, differed by only a single amino acid residue substitution; each harbored the HLA-A*02:01 molecule at the floor of their binding grooves. Allele-specific peptide motifs for each HLA-A2 subtype differed substantially from the HLA-A*02:01 motif in the dominant anchor residues (36). Although the carrier- and gene frequency of HLA-A*02:06 in Japanese patients with CM-SJS/TEN with Socs was significantly higher than in the control group, the frequency of HLA-A*02:07 was similar in both groups (2). We found that the expression of HLA-A*02:07 but not of HLA-A*02:06 was associated with CM-SJS/TEN with SOC in the Han Chinese patients (26).

No HLA- B*44:03 expression was detected in Han Chinese SJS/TEN patients or the controls (26), a finding compatible with earlier studies that showed that only 0.41–0.63% of the Taiwanese Han Chinese population harbored HLA-B*44:03 (37, 38). This observation suggests a genetic diversity in the pathogenesis of SJS among different ethnic groups although, because the number of samples was small, these studies must be expanded to include more samples.

**United Kingdom**

Our UK collaborators found that 9 of their 28 patients with SJS/TEN with SOC (32%) had taken cold medicines (39). Together with our UK collaborators we analyzed the association of HLA-A, HLA-B, and HLA-C alleles with SJS/TEN in 33 patients residing in the UK (28 patients with- and 5 without SOC) and in age-matched controls. There was a statistically significant and novel negative allele association with HLA-B*07:02 (25 patients, 15 controls; \( OR = 0.16, p = 0.012 \)) and with HLA-C*07:02 (25 patients, 15 controls; \( OR = 0.09, p = 0.030 \)) in a sub-group of European ancestry SJS/TEN patients (both with and without SOC) but not in their controls. This finding identified these alleles as being protective (39). Interestingly, a focus on European ancestry patients with SJS/TEN with SOC revealed only the association with HLA-B*07:02 (23 patients, 15 controls; \( OR = 0.17, p = 0.027 \)), but not with HLA-C*07:02. When the focus was directed on European ancestry patients with CM-SJS/TEN with SOC, both associations with HLA-B*07:02 and HLA-C*07:02 disappeared (39). Thus, although HLA-B*07:02 was associated with SJS/TEN with SOC in European ancestry, it may not be a biomarker for CM-SJS/TEN with SOC in that population.

Because the number of samples was small, these studies must be expanded to include more samples.

**DISCUSSION**

A summary of our collaborative HLA analyses is shown in Table 1. It shows that HLA-B*44:03 was significantly associated with CM-SJS/TEN with SOC in the Japanese (2), in Brazilians, especially European ancestry Brazilians (3, 24, 32), in Indian patients (3, 33), and in Thais (25, 34). HLA-A*02:06 was significantly associated with CM-SJS/TEN with SOC in the Japanese (2) and in Koreans (3, 31). Ma et al. (26) suggested that HLA-A*02:07, differing by only a single amino acid residue substitution from HLA-A*02:06, might be significantly associated with CM-SJS/TEN with SOC in Taiwanese patients.

The acetaminophen-associated HLA type might be a little different between CM-SJS/TEN with SOC in Japanese- (HLA-A*02:06) (30) and Thai patients (HLA-B*44:03—HLA-C*07:01 haplotype) (34). Moreover, the dipyrone-associated HLA types for CM-SJS/TEN with SOC in the Brazilian population were HLA-B*44:03 and HLA-DQB1*04:02 in European ancestry, and HLA-C*05:01 in mixed raced ancestry (32).

We think that a common function of cold medicines such as acetaminophen, dipyrone, and NSAIDs is highly implicated in the onset of SJS/TEN with SOC (4, 23, 30, 40).

The common function of cold medicines is the suppression of prostaglandin E2 (PGE2) production which suppress mucocutaneous inflammation. PGE2 acts on EP3 (PGE2 receptor 3) in the epidermis (41) and the mucosal epithelium (42, 43) and negatively regulates mucocutaneous inflammation. We suspect that cold medicines that include acetaminophen and dipyrone could upregulate inflammatory responses by suppressing the production of PGE2 which suppress mucocutaneous inflammation, that they augment abnormal immune responses,
| Country | Number of SJS/TEN with SOC cases | Number of SJS/TEN with SO cases | HLA-A | HLA-B | HLA-C |
|---------|-------------------------------|-------------------------------|-------|-------|-------|
| Japan   | 40 cases vs. 120 controls     | 76.0% (76/100)                | -     | -     | -     |
| Europe  | 26 cases vs. 15 controls       | 68.6% (151/220)               | -     | -     | -     |
| Korea   | 28 cases vs. 50 controls       | -                              | -     | -     | -     |
| India   | 27 cases vs. 9 controls        | -                              | -     | -     | -     |
| Thailand| 23 cases vs. 15 controls       | -                              | -     | -     | -     |
| Taiwan  | 9 cases vs. 15 controls        | -                              | -     | -     | -     |
| Brazil  | 13 cases vs. 16 controls       | -                              | -     | -     | -     |
| KREPA   | 23 cases vs. 15 controls       | -                              | -     | -     | -     |
| Italy   | 22 cases vs. 8 controls        | -                              | -     | -     | -     |

**Table 1** Carrier frequencies of each country.

**HLA-A**

- **Japan**: HLA-A*11:01
  - OR = 21.2, p = 0.001
- **Europe**: HLA-A*02:07
  - OR = 9.0, p = 0.0002
- **Korea**: HLA-A*02:07
  - OR = 3.4, p = 0.001
- **India**: HLA-A*33:03
  - OR = 12.3, p = 0.0028
- **Thailand**: HLA-A*33:03
  - OR = 5.6, p = 0.0003
- **Taiwan**: HLA-A*33:03
  - OR = 10, p = 0.0003
- **Brazil**: HLA-A*02:07
  - OR = 27, p = 0.0001

**HLA-B**

- **Japan**: HLA-B*57:01
  - OR = 0.17, p = 0.23
- **Europe**: HLA-B*07:02
  - OR = 0.05, p = 0.17
- **Korea**: HLA-B*07:02
  - OR = 0.15, p = 0.016
- **India**: HLA-B*07:02
  - OR = 0.0004
- **Thailand**: HLA-B*07:02
  - OR = 0.0004
- **Taiwan**: HLA-B*07:02
  - OR = 0.0004
- **Brazil**: HLA-B*07:02
  - OR = 0.0004

**HLA-C**

- **Japan**: HLA-C*12:03
  - OR = 113, p = 0.008
- **Europe**: HLA-C*07:01
  - OR = 2.0, p = 0.006
- **Korea**: HLA-C*07:01
  - OR = 2.7, p = 0.008
- **India**: HLA-C*07:01
  - OR = 4.1, p = 0.008
- **Thailand**: HLA-C*07:01
  - OR = 3.4, p = 0.008
- **Taiwan**: HLA-C*07:01
  - OR = 2.1 × 10⁻³, p = 0.008
- **Brazil**: HLA-C*07:01
  - OR = 3.4, p = 0.008

**Number of SJS/TEN with SOC cases**

- **Japan**: 40 cases vs. 120 controls
- **Europe**: 26 cases vs. 15 controls
- **Korea**: 28 cases vs. 50 controls
- **India**: 27 cases vs. 9 controls
- **Thailand**: 23 cases vs. 15 controls
- **Taiwan**: 9 cases vs. 15 controls
- **Brazil**: 13 cases vs. 16 controls
- **Korea**: 23 cases vs. 15 controls
- **Italy**: 22 cases vs. 8 controls

**Number of SJS/TEN with SO cases**

- **Japan**: 76 cases vs. 100 controls
- **Europe**: 151 cases vs. 220 controls
- **Korea**: 151 cases vs. 220 controls
- **India**: 141 cases vs. 220 controls
- **Thailand**: 141 cases vs. 220 controls
- **Taiwan**: 141 cases vs. 220 controls
- **Brazil**: 141 cases vs. 220 controls
- **Korea**: 141 cases vs. 220 controls
- **Italy**: 141 cases vs. 220 controls
and that they elicit the induction of SJS/TEN with SOC (4, 23, 30, 40).

Besides HLA types, we investigated other SJS/TEN with SOC susceptibility genes. Our genome-wide association study revealed IKZF1 to be a susceptibility gene for CM-SJS/TEN with SOC in Japanese-, Korean-, and Indian populations (6). It was also significantly associated with CM-SJS/TEN with SOC in Thai patients (44). Consequently, IKZF1 may be a universal marker for CM-SJS/TEN with SOC (6, 44). Elsewhere (45) we documented that IKZF1 regulates mucocutaneous inflammation. We reported that IKZF1 transgenic mice developed spontaneous mucocutaneous inflammations such as ocular surface- and oral inflammation and dermatitis (45).

In the Japanese population we identified PTGER3 as a susceptibility gene for CM-SJS/TEN with SOC (8), and we reported that HLA-A*02:06 and PTGER3 polymorphisms exerted additive effects in Japanese and Korean patients with CM-SJS/TEN with SOC (OR = 10.8 and 14.2, respectively) (46).

We also suggest that in addition to microbial infections and cold medicines, the combination of multiple gene polymorphisms and their interactions contributes strongly to the onset of CM-SJS/TEN with SOC. Abnormal Innate Immunity might strongly contribute the pathology of SJS/TEN with SOC (4, 23).

Despite the genetic diversity in SJS/TEN with SOC among different ethnic groups, to prevent its onset and to reduce the incidence of blindness due to SJS/TEN, efforts must continue to identify the genetic predisposition for SJS/TEN with SOC.

AUTHOR CONTRIBUTIONS
MU wrote this mini review.

FUNDING
This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government, by the JSPS Core-to-Core Program, A. Advanced Research Networks, and partly supported by grants-in-aid for scientific research from the Japanese Ministry of Health, Labor, and Welfare.

REFERENCES
1. Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Am J Ophthalmol.* (2015) 160:228–37 e2. doi: 10.1016/j.ajo.2015.05.002
2. Ueta M, Kaniwa N, Sotozono C, Tokunaga K, Saito Y, Sawai H, et al. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. *Sci Rep.* (2014) 4:4862. doi: 10.1038/srep04862
3. Ueta M, Kannabiran C, Wakamatsu TH, Kim MK, Yoon KC, Seo KY, et al. Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications. *Sci Rep.* (2014) 4:3981. doi: 10.1038/srep03981
4. Ueta M, Kinoshita S. Ocular surface inflammation is regulated by innate immunity. *Prog Retin Eye Res.* (2012) 31:551–75. doi: 10.1016/j.preteyeres.2012.05.003

5. Ueta M, Sawai H, Shingaki R, Kawai Y, Sotozono C, Kojima K, et al. Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. *J Hum Genet.* (2017) 62:485–9. doi: 10.1038/jhg.2016.160
6. Ueta M, Sawai H, Sotozono C, Hitomi Y, Kaniwa N, Kim MK, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. *J Allergy Clin Immunol.* (2015) 135:1538–45 e17. doi: 10.1016/j.jaci.2014.12.1916
7. Ueta M, Sotozono C, Inatomi T, Kojima K, Tashiro K, Hamuro J, et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. *Br J Ophthalmol.* (2007) 91:962–5. doi: 10.1136/bjo.2006.113449
8. Ueta M, Sotozono C, Nakano M, Taniguchi T, Yagi T, Tokuda Y, et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. *J Allergy Clin Immunol.* (2010) 126:1218–25 e10. doi: 10.1634/jaci.2010.08.007
9. Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. *Am J Ophthalmol.* (2007) 143:367–8. doi: 10.1016/j.ajo.2006.09.029
10. Sotozono C, Ang LP, Koizumi N, Higashihara H, Ueta M, Inatomi T, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. *Ophthalmology.* (2007) 114:1294–302. doi: 10.1016/j.ophtha.2006.10.029
11. Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z, et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. *Ophthalmology.* (2009) 116:685–90. doi: 10.1016/j.ophtha.2008.12.048
12. Mockenhaupt M, Vibold C, Dunant A, Naldi L, Haley S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs, the EuroSCAR-study. *J Invest Dermatol.* (2008) 128:35–44. doi: 10.1093/jid/sjijd701033

13. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. *Allergol Int.* (2007) 56:419–25. doi: 10.2322/allergolint.O-07-483
14. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature.* (2004) 428:486. doi: 10.1038/428486a
15. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. *Hum Mol Genet.* (2011) 20:1034–41. doi: 10.1093/hmg/ddq537
16. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. *N Engl J Med.* (2011) 364:1314–43. doi: 10.1056/NEJMoa1013297
17. Mockenhaupt M, Wang CW, Hung SI, Sekula P, Schmidt AH, Pan RY, et al. HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. *Allergy.* (2019) 74:2227–30. doi: 10.1111/all.13821
18. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proc Natl Acad Sci USA.* (2005) 102:4134–9. doi: 10.1073/pnas.0409500102
19. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. *Hum Mol Genet.* (2011) 20:1034–41. doi: 10.1093/hmg/ddq537
21. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B locus in Japanese patients with anti-epileptic and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomica. (2008) 9:1617–22. doi: 10.2217/14622416.9.11.1617

22. Lee HS, Ueta M, Kim MK, Seo KY, Sotozono C, Kinoshita S, et al. Analysis of ocular manifestation and genetic association of allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrosis in South Korea. Cornea. (2016) 35:199–204. doi: 10.1097/ICO.0000000000000708

23. Ueta M. Results of detailed investigations into stevens-johnson syndrome with severe ocular complications. Invest Ophthalmol Vis Sci. (2018) 59:DE5183–91. doi: 10.1167/iovs.17-23537

24. Wakahatsu TH, Ueta M, Tokunaga K, Okada Y, Loureiro RR, Costa KA, et al. Human leukocyte antigen class I genes associated with Stevens-Johnson syndrome and severe ocular complications following use of cold medicine in a Brazilian population. JAMA Ophthalmol. (2017) 135:355–60. doi: 10.1001/jamaophthalmology.2017.0074

25. Jongkhajornpong P, Lekhanont K, Pisuchpen P, Chantaren P, Prabhasawat P, et al. Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. Br J Ophthalmol. (2018) 102:1303–7. doi: 10.1136/bjo.2017-311823

26. Ma KS, Chung WH, Hsueh YJ, Chen SY, Tokunaga K, Kinoshita S, et al. Human leukocyte antigen association of patients with Stevens-Johnson syndrome/toxic epidermal necrosis with severe ocular complications in Han Chinese. Br J Ophthalmol. (2021). doi: 10.1136/bjophthalmol-2020-317305. [Epub ahead of print].

27. Lee HK, Yoon KC, Seo KY, Ueta M, Kim MK. Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea. J Allergy Clin Immunol Pract. (2017) 6:700–2.e2. doi: 10.1016/j.jaip.2017.09.001

28. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of IL10 polymorphisms with Stevens-Johnson syndrome. J Allergy Clin Immunol. (2007) 120:1457–9. doi: 10.1016/j.jaci.2007.07.048

29. Ueta M. Genetic predisposition to stevens-johnson syndrome with severe ocular surface complications. Cornea. (2015) 34(Suppl. 11):S158–65. doi: 10.1097/ICO.0000000000000605

30. Ueta M, Nakamura R, Saito Y, Tokunaga K, Sotozono C, Yabe T, et al. Association of HLA class I and II gene polymorphisms with acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Japanese individuals. Hum Genome Var. (2019) 6:50. doi: 10.1080/14434910-00082-6

31. Jun I, Rim JH, Kim MK, Yoon KC, Joo CK, Kinoshita S, et al. Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. Br J Ophthalmol. (2019) 103:573–6. doi: 10.1136/bjo-2018-331363

32. Wakahatsu TH, Ueta M, Inoue C, Costa KA, Sakano LY, Sallum JMF, et al. Human leukocyte antigen class I and II genes associated with dipyrimidine-related Stevens-Johnson syndrome and severe ocular complications in a Brazilian population. Ocul Surf. (2021) 20:173–5. doi: 10.1016/j.jtos.2021.02.008

33. Kannabiran C, Ueta M, Sangwan V, Rathi V, Basu S, Tokunaga K, et al. Association of human leukocyte antigen class I genes with Stevens-Johnson syndrome with severe ocular complications in an Indian population. Sci Rep. (2017) 7:15960. doi: 10.1038/s41598-017-15965-7

34. Jongkhajornpong P, Ueta M, Lekhanont K, Prabhasawat P, Chantaren P, et al. Association of HLA polymorphisms and acetaminophen-related Stevens-Johnson syndrome with severe ocular complications in Thai population. Br J Ophthalmol. (2020). doi: 10.1136/bjophthalmol-2020-317315. [Epub ahead of print].

35. Ueta M. Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrosis with severe ocular complications-phenotypes and genetic predispositions. Taiwan J Ophthalmol. (2016) 6:108–18. doi: 10.1016/j.tjo.2016.06.001

36. Sato T, Kamikawaji N, Kimura A, Date Y, Savaie CJ, Nakashima H, et al. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol. (1995) 155:4749–56.

37. Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy. (2012) 97:149–66. doi: 10.1159/00035627

38. Wen SH, Lai MJ, Yang KL. Human leukocyte antigen-A, -B, and -DRB1 haplotypes of cord blood units in the Tzu Chi Taiwan cord blood bank. Hum Immunol. (2008) 69:430–6. doi: 10.1016/j.jhamimm.2008.05.012

39. Butt GF, Hassan A, Wallace GR, Kinoshita S, Ahmad M, Ueta M, et al. Human leukocyte antigen B*0702 is protective against ocular Stevens-Johnson syndrome/toxic epidermal necrosis in the UK population. Rep. Sci. (2021) 11:2928. doi: 10.1038/s41598-021-82400-3

40. Ueta M. Stevens-Johnson syndrome/toxic epidermal necrosis with severe ocular complications. Expert Rev Clin Immunol. (2020) 16:285–91. doi: 10.1080/17446660.2020.1729128

41. Honda T, Matsuoka T, Kabashima K, Miyachi Y, Narumiya S. Prostaglandin E2(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol. (2009) 124:809–18 e2. doi: 10.1016/j.jaci.2009.04.029

42. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y, Tanaka S, et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol. (2005) 6:524–31. doi: 10.1038/ni1188

43. Ueta M, Matsuoka T, Narumiya S, Kinoshita S. Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis. J Allergy Clin Immunol. (2009) 123:466–71. doi: 10.1016/j.jaci.2008.09.044

44. Chantaren P, Jongkhajornpong P, Ueta M, Prabhasawat P, Lekhanont K, Pisuchpen P, et al. Association of IKZF1 SNPs in cold medicine-related Stevens-Johnson syndrome in Thailand. Clin Transl Allergy. (2019) 9:61. doi: 10.1186/s13601-019-0300-9

45. Ueta M, Hamuro J, Nishigaki H, Nakamura N, Shinomiya K, Mizushima K, et al. Mucocutaneous inflammation in the Ikaros Family Zinc Finger 1-keratin 3-specific transgenic mice. Allergy. (2017) 73:395–404. doi: 10.1111/all.13308

46. Ueta M, Tokunaga K, Sotozono C, Sawai H, Yoon KC, Kim MK, et al. HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related Stevens-Johnson syndrome with severe ocular complications. Hum Genome Var. (2015) 2:15023. doi: 10.1038/hgv.2015.23

Conflict of Interest: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Ueta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.